STOCK TITAN

Cytosorbents agrees to roughly $4M direct offering

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Cytosorbents Corp. (CTSO) entered into agreements for an approximately $4.0 million registered direct offering, expected to close on or about November 20, 2026, subject to customary closing conditions. The offering includes 556,681 common shares at $4.94 each, 96,527 shares to directors and certain executive officers at $5.18 each, and pre-funded warrants for up to 151,822 shares at $4.939 each, exercisable for one share at $0.001. Estimated net proceeds are approximately $3.5 million.

Under a concurrent Avenue loan amendment, the company expects to repay $3.0 million of principal in cash, plus a $52,500 prepayment fee and $270,000 final payment, and satisfy another $2.25 million with shares priced at $4.94. That share settlement includes 202,429 registered shares for $1.0 million of principal and 253,036 unregistered shares for $1.25 million. The expected $5.25 million principal reduction would leave $12.25 million outstanding. The interest-only period extends through March 31, 2028, and maturity is July 1, 2028; the company estimates approximately $0.7 million in interest savings over 12 months. Net proceeds are intended for loan repayment and general corporate and working capital purposes.

1 point · 1 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 0 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Major point. Forward-looking: it has not happened yet and may not happen.Expected $5.25 million principal reduction would leave $12.25 million outstanding. 32% of market cap

Negative

  • None.

Filing Explained

The Avenue amendment provides conversion options—not completed conversions—for lenders covering up to $3.0 million of principal at $6.916 per share and, from the earlier of FDA Marketing Approval or January 1, 2028, up to another $3.125 million at $8.645 per share. Absent stockholder approval, a 19.99% exchange cap applies; if exercised, the principal would be settled with new shares, reducing existing holders’ percentage ownership.

Item 1.01 Entry into a Material Definitive Agreement Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 3.02 Unregistered Sales of Equity Securities Securities
The company sold equity securities in a private placement or other unregistered transaction.
Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Gross cash proceeds Approximately $4.0 million Expected from the offering, before fees and expenses
Net proceeds Approximately $3.5 million Company estimate; intended for loan repayment and general corporate and working capital purposes
Common shares offered 556,681 shares at $4.94 per share Offering to institutional and accredited investors
Shares to directors and certain executive officers 96,527 shares at $5.18 per share Offering
Pre-funded warrants Up to 151,822 shares; $4.939 purchase price per warrant and $0.001 exercise price per share Immediately exercisable; subject to beneficial ownership limitation
Avenue principal satisfied with shares $2.25 million Under the Avenue loan amendment
Expected loan principal reduction Approximately $5.25 million, to $12.25 million outstanding Upon completion of the cash repayment and share issuance
Estimated interest savings Approximately $0.7 million over 12 months Company estimate associated with the Avenue amendment
Pre-Funded Warrants financial
"Pre-Funded Warrants to purchase up to an aggregate of 151,822 shares"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
Beneficial Ownership Limitation financial
"subject to the Beneficial Ownership Limitation described below"
A beneficial ownership limitation is a rule that caps the percentage of a company’s shares an investor can be treated as owning or controlling for voting, regulatory or tax purposes. It matters to investors because it can restrict how many shares a person or group can buy or vote, affect takeover chances, and influence share liquidity and value — like a speed limit that prevents any single driver from taking over the whole road.
interest-only period financial
"extends the interest-only period through March 31, 2028"
A period during a loan when the borrower pays only the interest charges and none of the original principal, so monthly payments are lower but the loan balance does not shrink. For investors, this affects cash flow and risk: borrowers may have higher near-term liquidity but face larger payments or refinancing later, which can influence a company’s ability to pay dividends, meet obligations, or require new financing — similar to paying rent on borrowed money before starting to pay it down.
cash-burn threshold financial
"increases the applicable cash-burn threshold to $3,200,000"
exchange cap financial
"and a 19.99% exchange cap, absent requisite stockholder approval"
Trading Price financial
"at 140% of the defined Trading Price"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much cash does CTSO expect to raise?

CTSO expects approximately $4.0 million in gross cash proceeds and estimates net proceeds of approximately $3.5 million. The company intends to use the net proceeds for loan repayment and general corporate and working capital purposes.

How much will CTSO's Avenue debt be reduced?

The Avenue loan principal is expected to fall by approximately $5.25 million, to $12.25 million outstanding, after a $3.0 million cash principal repayment and a further $2.25 million principal settlement in shares. The transactions are expected to occur substantially concurrently with the offering's closing, subject to applicable conditions.

What are the terms of CTSO's pre-funded warrants?

The pre-funded warrants are immediately exercisable for one share at $0.001 per share and may be exercised until all are exercised in full. A holder cannot exercise to the extent that doing so would increase its and its affiliates' beneficial ownership above 4.99%, or 9.99% if elected, subject to the stated ownership limitation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001175151 0001175151 2026-11-19 2026-11-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 19, 2026

 

CYTOSORBENTS CORPORATION

(Exact name of registrant as specified in its charter) 

 

Delaware   001-36792   98-0373793
(State or other jurisdiction
of incorporation)
  (Commission
File Number)
  (IRS Employer
Identification No.)

 

305 College Road East, Princeton, New Jersey

  08540
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (973) 329-8885

 

 
(Former name or former address, if changed since last report.)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, $0.001 par value CTSO The Nasdaq Stock Market LLC
(Nasdaq Capital Market)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Item 1.01 Entry into a Material Definitive Agreement.

 

On November 19, 2026, CytoSorbents Corporation (the “Company”), a Delaware corporation, entered into two securities purchase agreements (collectively, the “Purchase Agreements”) with certain institutional and accredited investors (collectively, the “Purchasers”), for the sale by the Company directly to the Purchasers (the “Offering”) of (i) an aggregate of 556,681 shares (the “Common Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a purchase price of $4.94 per share, and 96,527 shares of Common Stock to the Company’s directors and certain executive officers at an offering price of $5.18 per share, which was the consolidated closing bid price of our Common Stock on The Nasdaq Capital Market on November 18, 2026, and (ii) to certain Purchasers, in lieu of Common Stock, pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to an aggregate of 151,822 shares of Common Stock (the “Pre-Funded Warrant Shares,” together with the Common Shares, the “Shares”), at a purchase price of $4.939 per Pre-Funded Warrant, equal to the purchase price per Common Share less $0.001, each exercisable for one share of Common Stock at an exercise price of $0.001 per Pre-Funded Warrant Share. The Shares and Pre-Funded Warrants are referred to herein as the “Securities.”

 

In connection with the Offering, H.C. Wainwright & Co., LLC (“Wainwright”) is acting as exclusive placement agent for the Offering. WBB Securities, LLC (“WBB”) is acting as financial advisor for the Offering, and will receive a financial advisory fee of $30,000 in connection therewith.

 

The Offering is expected to close on or about November 20, 2026, subject to satisfaction of customary closing conditions set forth in the Purchase Agreements. The gross proceeds from the Offering, before deducting placement agent fees, financial advisor fees and other offering expenses payable by the Company, will be approximately $4.0 million. The Company estimates that net proceeds from the Offering will be approximately $3.5 million. The Company currently intends to use the net proceeds from the Offering for (i) the repayment of $3.0 million of outstanding principal under the Company’s Loan Agreement with Avenue (as defined below), together with a $52,500 prepayment fee and a $270,000 final payment, and (ii) general corporate and working capital purposes.

 

The Securities were offered by the Company pursuant to a shelf registration statement on Form S-3 (File No. 333-281062), which was initially filed with the Securities and Exchange Commission (the “Commission”) on July 26, 2024 and was declared effective by the Commission on September 30, 2024 (the “Registration Statement”), including the base prospectus dated September 30, 2024, as supplemented by a prospectus supplement filed with the Commission on November 20, 2026, pursuant to Rule 424(b)(5) under the Securities Act of 1933, as amended (the “Securities Act”). In addition, the Registered Shares (as defined below) to be issued to Avenue pursuant to the Avenue Amendment, as described below, are being offered pursuant to the Registration Statement, the base prospectus included therein and the prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act.

 

The Pre-Funded Warrants are exercisable immediately and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full, subject to the Beneficial Ownership Limitation described below. A holder of a Pre-Funded Warrant may not exercise any such Pre-Funded Warrant to the extent that such exercise would result in the number of shares of Common Stock beneficially owned by such holder and its affiliates exceeding 4.99% or 9.99% (at the election of the holder) of the total number of shares of Common Stock outstanding immediately after giving effect to the exercise, which percentage may be increased or decreased at the holder’s election not to exceed 9.99% (the “Beneficial Ownership Limitation”).

 

The Purchase Agreements contain customary representations, warranties, covenants and agreements by the Company and the Purchasers, customary conditions to closing, indemnification obligations of the Company and other obligations of the parties. The representations, warranties and covenants contained in the Purchase Agreements were made only for purposes of the Purchase Agreements and as of specific dates, were solely for the benefit of the parties thereto, and may be subject to qualifications and limitations agreed upon by the contracting parties, including standards of materiality and knowledge that may differ from those applicable to investors generally. Accordingly, such representations, warranties and covenants should not be relied upon as characterizations of the actual state of facts or condition of the Company.

 

 

 

 

Placement Agent Common Stock Warrant

 

On October 5, 2026, the Company entered into an engagement letter with Wainwright in connection with the Offering (as amended, the “Engagement Letter”), pursuant to which Wainwright agreed to serve as the exclusive placement agent in connection with the Offering. As compensation for such placement agent services, the Company has agreed to pay Wainwright an aggregate cash fee equal to 6.0% of the aggregate gross proceeds received by the Company from the Offering, reduced to 3.0% with respect to gross proceeds received from certain existing stockholders of the Company identified in the Engagement Letter, together with their respective affiliates and affiliated funds and accounts (the “Company Investors”), and to issue to Wainwright or its designees warrants (the “Placement Agent Warrants”) to purchase a number of shares of Common Stock (the “Placement Agent Warrant Shares”) equal to 6.0% of the aggregate number of shares of Common Stock (or Common Stock equivalents, if applicable) issued in the Offering, reduced to 3.0% with respect to the shares of Common Stock (or pre-funded warrants in lieu thereof) purchased by the Company Investors. The Company also agreed to pay to Wainwright non-accountable expenses of $50,000, up to $100,000 for its fees and expenses of legal counsel and other out-of-pocket expenses and closing costs, including clearing costs not to exceed $15,950, subject to an aggregate cap of $165,950 on such expenses and reimbursements. The Engagement Letter also includes indemnification obligations of the Company and other provisions customary for transactions of this nature.

 

The Placement Agent Warrants, exercisable into 18,078 shares of Common Stock, will have an exercise price of $6.175 per share, subject to customary adjustment as provided therein, will be immediately exercisable and will expire on November 19, 2031. Under the terms of the Placement Agent Warrants, the Company may not effect the exercise of any portion of any Placement Agent Warrants, and a holder will not have the right to exercise any portion of any Placement Agent Warrants, which, upon giving effect to such exercise, would cause a holder (together with its affiliates) to own more than a specified beneficial ownership limitation of 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise, as such percentage ownership is determined in accordance with the terms of the Placement Agent Warrants. However, any holder may increase or decrease such percentage to any other percentage not in excess of 9.99%, provided that any increase in such percentage shall not be effective until 61 days after such notice is delivered to the Company.

 

The Placement Agent Warrants and the shares of Common Stock issuable upon exercise of the Placement Agent Warrants are not being registered under the Securities Act, were not offered pursuant to the Registration Statement and were offered pursuant to the exemption from registration provided by Section 4(a)(2) of the Securities Act, and Rule 506(b) promulgated thereunder.

 

Third Amendment to the Avenue Capital Loan Agreement

 

Concurrently with the execution of the Purchase Agreements relating to the Offering, the Company entered into the Third Amendment to Loan Documents (the “Avenue Amendment”), dated November 19, 2026, to its existing Loan and Security Agreement with Avenue Capital Group, as amended (the “Loan Agreement”), pursuant to which the Company agreed to restructure certain of its outstanding indebtedness under the Loan Agreement.

 

Under the terms of the Avenue Amendment, the Company agreed to (i) repay approximately $3.3 million of outstanding indebtedness under the Loan Agreement in cash, consisting of $3.0 million in outstanding principal, a $52,500 prepayment fee and a $270,000 final payment, and (ii) satisfy an additional $2.25 million of outstanding principal through the issuance of shares of Common Stock to Avenue Venture Opportunities Fund, L.P. (“Avenue”) in lieu of repayment in cash. Such shares will be issued at a price per share equal to the purchase price per share of Common Stock sold in the Offering, or $4.94 per share. Of these shares, 202,429 shares, representing the satisfaction of $1.0 million of outstanding principal (the “Registered Shares”), are being issued pursuant to the Registration Statement, the related prospectus and the applicable prospectus supplement, and the remaining 253,036 shares of Common Stock (the “Unregistered Shares” and, together, with the Registered Shares, the “Avenue Shares”), representing the satisfaction of $1.25 million of outstanding principal, are being offered pursuant to the exemption from registration provided in Section 4(a)(2) under the Securities Act, and Rule 506(b) promulgated thereunder.

 

The cash repayment and issuance of shares of Common Stock pursuant to the Avenue Amendment are expected to occur substantially concurrently with the closing of the Offering, subject to satisfaction of the applicable conditions under the Avenue Amendment. Upon issuance of all shares in satisfaction of the additional $2.25 million of outstanding principal, such principal will be deemed paid and satisfied in full. Upon completion of the $3.0 million cash principal repayment and the issuance of shares in satisfaction of the additional $2.25 million of outstanding principal, the Company expects the outstanding principal amount under the Loan Agreement to be reduced by approximately $5.25 million in the aggregate, to a remaining total of $12.25 million of outstanding principal.

 

 

 

 

The Avenue Amendment also (i) extends the interest-only period through March 31, 2028, subject to a possible three-month extension upon achievement of FDA Marketing Approval and the absence of a continuing event of default, and establishes a maturity date of July 1, 2028; (ii) revises the lenders’ rights to convert up to $3,000,000 of outstanding principal at 140% of the defined Trading Price, or $6.916 per share, and upon the earlier of FDA Marketing Approval or January 1, 2028, up to an additional $3,125,000 of outstanding principal at 175% of that Trading Price, or $8.645 per share, in each case subject to the conditions and limitations in the Avenue Amendment; (iii) imposes a 4.99% beneficial ownership limitation, subject to adjustment on notice, and a 19.99% exchange cap, absent requisite stockholder approval, on issuances upon exercise of the applicable conversion options and warrants; and (iv) increases the applicable cash-burn threshold to $3,200,000 for testing periods through December 31, 2026, with a $2,000,000 threshold otherwise applicable under the amended covenant.

 

The Avenue Amendment further provides for a $250,000 back-end fee payable to Avenue on July 1, 2028 (or earlier upon repayment or acceleration of the obligations), subject to waiver if Avenue realizes the specified 300% net-profit threshold on the Avenue Shares. It also provides Avenue registration rights with respect to the shares issued in the transaction exempt from registration under the Securities Act, pursuant to which the Company has agreed to file a resale registration statement within 60 days after the Avenue Amendment effective date and to use commercially reasonable efforts to cause it to become effective within 90 days after that date, subject to the terms of the Avenue Amendment. Certain shares issuable to the Lenders upon exercise of conversion options or warrants are subject to a transfer restriction tied to the prohibition period under the Securities Purchase Agreement, as described in the Avenue Amendment.

 

The foregoing descriptions of the Pre-Funded Warrants, the Placement Agent Warrants, each of the Purchase Agreements and the Avenue Amendment are not complete and are qualified in their entirety by reference to the full text of the Form of Pre-Funded Warrant, the Form of Placement Agent Warrant, each of the Forms of Purchase Agreement and the Avenue Amendment, which are filed herewith as Exhibits 4.1, 4.2, 10.1, 10.2, and 10.3, respectively, to this Current Report on Form 8-K and are incorporated by reference herein.

 

A copy of the opinion of Morgan, Lewis & Bockius LLP relating to the legality of the issuance and sale of the Shares, the Pre-Funded Warrants and the Registered Shares in the Registered Direct Offering is filed as Exhibit 5.1 to this Current Report on Form 8-K.

 

This Current Report on Form 8-K does not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

 

Forward-Looking Statements

 

This Current Report on Form 8-K contains forward-looking statements that involve risks and uncertainties, such as statements related to the expected use of the proceeds from the Offering. There are a number of important factors that could cause actual results to differ materially from those indicated or implied by forward-looking statements. Accordingly, you are cautioned that these forward-looking statements are only predictions and are subject to risks, uncertainties and assumptions, including those referenced from time to time in the Company’s periodic reports and other filings with the SEC. You are cautioned not to place undue reliance on forward-looking statements, which are based on the Company’s current expectations and assumptions and speak only as of the date of this Current Report on Form 8-K. The Company does not intend to revise or update any forward-looking statement in this Current Report on Form 8-K as a result of new information, future events or otherwise, except as required by law.

 

Item 3.02 Unregistered Sales of Equity Securities.

 

The information under Item 1.01 of this Current Report on Form 8-K related to the Placement Agent Warrants, the Placement Agent Warrant Shares and the Unregistered Shares is incorporated herein by reference.

 

Item 7.01 Regulation FD Disclosure.

 

On November 20, 2026, the Company issued a press release relating to the items discussed in Item 1.01 of this Current Report on Form 8-K, a copy of which is furnished as Exhibit 99.1 hereto.

 

The information in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.

 

 

 

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit
No.
Description
4.1 Form of Pre-Funded Warrant
4.2 Form of Placement Agent Common Stock Warrant
5.1 Opinion of Morgan, Lewis & Bockius LLP
10.1 Form of Securities Purchase Agreement, dated November 19, 2026, by and between CytoSorbents Corporation and the purchasers named therein
10.2 Form of Securities Purchase Agreement, dated November 19, 2026, by and between CytoSorbents Corporation and the purchasers named therein
10.3 Third Amendment to Loan Documents, dated November 19, 2026, among CytoSorbents Corporation, Avenue Capital Management II, L.P., Avenue Venture Opportunities Fund, L.P. and Avenue Venture Opportunities Fund II, L.P.
23.1 Consent of Morgan, Lewis & Bockius LLP (included in Exhibit 5.1)
99.1 Press Release dated November 20, 2026
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

November 20, 2026 CytoSorbents Corporation
   
  By: /s/ Dr. Phillip P. Chan
    Name: Dr. Phillip P. Chan

 

 

 

 

Exhibit 99.1

 

CytoSorbents Announces $6.25 Million Common Stock Financing Priced At-the-Market under Nasdaq Rules and Concurrent Restructuring of Avenue Capital Credit Facility

 

$4.0 million registered direct offering of common stock, led by existing shareholders and management

 

$2.25 million of Avenue debt satisfied through the issuance of common stock at the same offering price

 

Total debt reduced by $5.25 million, to $12.25 million, saving approximately $0.7 million in interest over 12 months

 

Maturity extended one year to July 1, 2028; interest-only period extended 15 months through March 31, 2028

 

PRINCETON, N.J., November 20, 2026 -- CytoSorbents Corporation (NASDAQ: CTSO, the “Company”), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced a $6.25 million common stock financing.

 

Registered Direct Offering

 

The Company has entered into securities purchase agreements with certain institutional and accredited investors and certain insiders of the Company for the issuance and sale in a registered direct offering (the “Offering”) priced at-the-market under Nasdaq rules of (i) an aggregate of 556,681 shares (the “Common Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a purchase price of $4.94 per share, and 96,527 shares of Common Stock to the Company’s directors and certain executive officers at an offering price of $5.18 per share, which was the consolidated closing bid price of our Common Stock on The Nasdaq Capital Market on November 18, 2026, and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to an aggregate of 151,822 shares of Common Stock (the “Pre-Funded Warrant Shares,” together with the Common Shares, the “Shares”), at a purchase price of $4.939 per Pre-Funded Warrant, equal to the purchase price per Common Share less $0.001. Each Pre-Funded Warrant is immediately exercisable for one share of Common Stock at an exercise price of $0.001 per Pre-Funded Warrant Share until such Pre-Funded Warrants are exercised in full.

 

The Offering is expected to consist of approximately $4.0 million of gross cash proceeds, with approximately 75% of the Offering subscribed for by existing shareholders and members of the Company’s management and Board of Directors.

 

H.C. Wainwright & Co. is acting as exclusive placement agent for the Offering. WBB Securities LLC is acting as financial advisor in connection with the Offering.

 

 

 

 

The Offering is expected to close on or about November 20, 2026, subject to satisfaction of customary closing conditions. Gross proceeds from the Offering are expected to be approximately $4.0 million, before deducting placement agent fees, financial advisor fees and offering expenses payable by the Company. The Company intends to use the net proceeds for (i) the repayment of $3.0 million of outstanding principal under its existing loan agreement with Avenue Capital Group (“Avenue”), together with a $52,500 prepayment fee and a $270,000 final payment, and (ii) general corporate and working capital purposes.

 

Avenue Credit Facility Amendment

 

Concurrently with the Offering, the Company entered into the Third Amendment to Loan Documents (the “Avenue Amendment”), dated November 19, 2026, to its existing Loan and Security Agreement dated June 28, 2024, as amended, with Avenue. Key terms include:

 

·Debt reduction of $5.25 million: Repayment of $3.0 million of principal in cash from the Offering proceeds, plus a $52,500 prepayment fee and a $270,000 final payment, and satisfaction of $2.25 million of principal through the issuance of 455,465 shares of Common Stock to Avenue Venture Opportunities Fund, L.P. at the Offering price of $4.94 per share. Following these transactions, $12.25 million of principal will remain outstanding, down from $17.5 million. The Company expects to save approximately $0.7 million in interest expense over 12 months.

 

·Maturity extended one year: The maturity date is extended from July 1, 2027 to July 1, 2028.

 

·Interest-only period extended 15 months: Interest-only payments are extended through March 31, 2028, with a further three-month extension available if the Company has received FDA marketing approval for DrugSorb-ATR by that date, subject to other conditions.

 

  · New conversion rights: Avenue’s existing $2.0 million conversion right is replaced with the right to convert (i) up to $3.0 million of principal into Common Stock at $6.916 per share, equal to 140% of the $4.94 Offering price, exercisable at any time, and (ii) up to an additional $3.125 million of principal at $8.645 per share, equal to 175% of the Offering price, exercisable beginning on the earlier of FDA marketing approval of DrugSorb-ATR and January 1, 2028. Any conversion would further reduce the Company’s outstanding debt.

 

·Other terms: The Avenue Amendment also modifies certain beneficial ownership limitations and financial covenants, provides certain registration rights and provides for a back-end fee of $250,000, payable on July 1, 2028 (or earlier repayment) and waived if Avenue achieves a net profit of at least 300% on the initial $2.25 million repayment shares.

 

Of the shares issued to Avenue in satisfaction of $2.25 million of principal, shares satisfying $1.0 million of principal (the “Registered Shares”) will be issued pursuant to the Company’s effective shelf registration statement on Form S-3 (File No. 333-281062), and shares satisfying the remaining $1.25 million of principal will be issued in a transaction exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”). The shares issued to Avenue are in addition to the securities issued in the Offering and will not generate additional cash proceeds to the Company. The cash repayment and issuance of shares to Avenue in satisfaction of the Company’s indebtedness are expected to occur substantially concurrently with the closing of the Offering, subject to applicable closing conditions.

 

 

 

 

Registration and Offering Information

 

The Common Shares, Pre-Funded Warrants, Pre-Funded Warrant Shares and Registered Shares are being offered and sold pursuant to a “shelf” registration statement on Form S-3 (File No. 333-281062), which was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on September 30, 2024. The Offering is being made only by means of a prospectus supplement and accompanying prospectus forming part of the effective registration statement. A final prospectus supplement and accompanying prospectus relating to the Offering and the Registered Shares will be filed with the SEC. Electronic copies may be obtained, when available, on the SEC’s website at www.sec.gov or by contacting H.C. Wainwright & Co., LLC, 430 Park Avenue, 3rd Floor, New York, New York 10022, at placements@hcwco.com or (212) 856-5711.

 

The shares issued to Avenue in satisfaction of the remaining $1.25 million of principal are being issued in a transaction not involving a public offering and have not been registered under the Securities Act or applicable state securities laws. Such shares may not be offered or sold in the United States absent registration or an applicable exemption from registration. The Company has agreed to file a registration statement with the SEC covering the resale of these shares.

 

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, and there shall not be any offer, solicitation or sale of such securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

 

About CytoSorbents Corporation (NASDAQ: CTSO)

 

CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. CytoSorbents’ proprietary blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Cartridges filled with these beads can be used with standard blood pumps already in the hospital (e.g. dialysis, continuous renal replacement therapy or CRRT, extracorporeal membrane oxygenation or ECMO, and heart-lung machines), where blood is repeatedly recirculated outside the body, through our cartridges where toxic substances are removed, and then back into the body. CytoSorbents’ technologies are used in a number of broad applications. Specifically, two important applications are 1) the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and 2) the removal of inflammatory agents and toxins in common critical illnesses that can lead to massive inflammation, organ failure and patient death. The breadth of these critical illnesses includes, for example, sepsis, burn injury, trauma, lung injury, liver failure, cytokine release syndrome, and pancreatitis as well as the removal of liver toxins that accumulate in acute liver dysfunction or failure, and the removal of myoglobin in severe rhabdomyolysis that can otherwise lead to renal failure. In these diseases, the risk of death can be extremely high, and there are few, if any, effective treatments.

 

CytoSorbents’ lead product, CytoSorb®, is approved in the European Union and distributed in over 70 countries worldwide, with more than 300,000 devices used cumulatively to date. CytoSorb was originally launched in the European Union under CE mark as the first cytokine adsorber. Additional CE mark extensions were granted for bilirubin and myoglobin removal in clinical conditions such as liver disease and trauma, respectively, and for ticagrelor and rivaroxaban removal in cardiothoracic surgery procedures. CytoSorb has also received FDA Emergency Use Authorization in the United States for use in adult critically ill COVID-19 patients with impending or confirmed respiratory failure. CytoSorb is not yet approved or cleared in the United States.

 

 

 

 

In the U.S. and Canada, CytoSorbents is developing the DrugSorb™-ATR antithrombotic removal system, an investigational device based on an equivalent polymer technology to CytoSorb, to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs. It has received two FDA Breakthrough Device Designations: one for the removal of ticagrelor and another for the removal of the direct oral anticoagulants (DOAC) apixaban and rivaroxaban in a cardiopulmonary bypass circuit during urgent cardiothoracic surgery. The Company is actively pursuing regulatory approval of DrugSorb-ATR with the U.S. FDA and will pursue regulatory approval with Health Canada with better visibility from the FDA. DrugSorb-ATR is not yet granted or approved in either the U.S. or Canada.

 

The Company has numerous marketed products and products under development based upon this unique blood purification technology protected by many issued U.S. and international patents and registered trademarks, and multiple patent applications pending, including ECOS-300CY®, CytoSorb-XL™, HemoDefend-RBC™, HemoDefend-BGA™, VetResQ®, K+ontrol™, DrugSorb™, ContrastSorb, PuriFi®, HotSwap®, and others. For more information, please visit the Company’s website at https://ir.cytosorbents.com/ or follow us on Facebook and X.

 

Forward Looking Statements

 

This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, future targets and outlooks for our business, representations and contentions, and the outcome of our regulatory submissions, and are not historical facts and typically are identified by use of terms such as “may,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management’s current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, statements regarding the completion and timing of the Offering, the satisfaction of customary closing conditions related to the Offering, and the intended use of net proceeds from the Offering, the expected repayment and conversion of indebtedness under the Avenue Amendment, the expected reduction in interest expense, any future exercise of Avenue’s conversion rights, and the timing and outcome of FDA review of DrugSorb-ATR, and the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 30, 2026, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. There can be no assurance that the Company will be successful in maintaining its listing of its common stock on the Nasdaq Capital Market. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.

 

U.S. Company Contact:

 

Peter J. Mariani, Chief Financial Officer

 

305 College Road East

 

Princeton, NJ 08540

 

ir@cytosorbents.com

 

 

Filing Exhibits & Attachments

10 documents

Keep reading